Detection of an endogenous urinary biomarker associated with CYP2D6 activity using global metabolomics (vol 15, pg 1947, 2014)

被引：0
|
作者：
Tay-Sontheimer, J.
Shireman, L. M.
Beyer, R. P.
机构：
来源：
PHARMACOGENOMICS | 2015年 / 16卷 / 08期
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：913 / 913
页数：1
相关论文
共 50 条
  • [41] Effect of CYP2D6 genotype on flecainide pharmacokinetics in Japanese patients with supraventricular tachyarrhythmia (vol 62, pg 919, 2006)
    Doki, Kosuke
    Homma, Masato
    Kuga, Keisuke
    Kusano, Kazutomi
    Watanabe, Shigeyuki
    Yamaguchi, Iwao
    Kohda, Yukinao
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2007, 63 (02) : 217 - 218
  • [42] Optimal sampling time to assess CYP2D6 activity using the plasma dextromethorphan/dextrorphan metabolic ratio
    Shiran, MR
    Abdul-Manap, R
    Rostami-Hodjegan, A
    Lennard, MS
    Tucker, GT
    JOURNAL OF PSYCHOPHARMACOLOGY, 2002, 16 (03) : A64 - A64
  • [43] Characterization of the CYP2D6*29 allele commonly present in a black Tanzanian population causing reduced catalytic activity (vol 11, pg 417, 2001)
    Wennerholm, A
    Johansson, I
    Hidestrand, M
    Bertilsson, L
    Gustafsson, LL
    IngelmanSundberg, M
    PHARMACOGENETICS, 2001, 11 (08): : 743 - 743
  • [44] INCREASED CYP2D6 ACTIVITY MAY BE ASSOCIATED WITH VENTRICULAR ARRHYTHMIAS (VA) IN PATIENTS WITH ACUTE MYOCARDIAL INFARCTION (AMI)
    Goryachkina, K.
    Burbello, A.
    Boldueva, S.
    Bergman, U.
    Bertilsson, L.
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2009, 105 : 80 - 80
  • [45] Linkage disequilibrium mapping identifies a 390 kb region associated with CYP2D6 poor drug metabolising activity
    Hosking L.K.
    Boyd P.R.
    Xu C.F.
    Nissum M.
    Cantone K.
    Purvis I.J.
    Khakhar R.
    Barnes M.R.
    Liberwirth U.
    Hagen-Mann K.
    Ehm M.G.
    Riley J.H.
    The Pharmacogenomics Journal, 2002, 2 (3) : 165 - 175
  • [46] Characterization and PCR-based detection of two different hybrid CYP2D7P/CYP2D6 alleles associated with the poor metabolizer phenotypes
    Daly, AK
    Fairbrother, KS
    Andreassen, OA
    London, SJ
    Idle, JR
    Steen, VM
    PHARMACOGENETICS, 1996, 6 (04): : 319 - 328
  • [47] Bioequivalence and absolute bioavailability of levomepromazine oblong and coated tablets in CYP2D6 phenotyped subjects (vol 33, pg 646, 1995)
    Bagli, M
    Hoflich, G
    Rao, ML
    Langer, M
    Baumann, P
    Kolbinger, M
    Barlage, U
    Kasper, S
    Moller, HJ
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 1996, 34 (02) : 92 - 92
  • [48] Relationship between plasma exposure of zolpidem and CYP2D6 genotype in healthy Korean subjects (vol 43, pg 976, 2020)
    Jung, Eui Hyun
    Lee, Choong-Min
    Byeon, Ji-Yeong
    Shin, Hyo-Bin
    Oh, Kyung-Yul
    Cho, Chang-Keun
    Lim, Chang Woo
    Jang, Choon-Gon
    Lee, Seok-Yong
    Lee, Yun Jeong
    ARCHIVES OF PHARMACAL RESEARCH, 2021, 44 (03) : 323 - 323
  • [49] Frequency of Undetected CYP2D6 Hybrid Genes in Clinical Samples: Impact on Phenotype Prediction (vol 40, pg 111, 2012)
    Black, J. L., III
    Walker, D. L.
    O'Kane, D. J.
    Harmandayan, M.
    DRUG METABOLISM AND DISPOSITION, 2012, 40 (06) : 1238 - 1238
  • [50] Relevance of CYP2D6 variability in first-episode schizophrenia patients treated with risperidone (vol 33, pg 236, 2012)
    Bartecek, Richard
    Jurica, Jan
    Zrustova, Jana
    Kasparek, Tomas
    Pindurova, Eva
    Zourkova, Alexandra
    NEUROENDOCRINOLOGY LETTERS, 2012, 33 (03) : II - II
12345